{"database": "lobbying", "table": "lobbying_activities", "rows": [[2301336, "24f41c09-609b-415c-998b-d28bd2562574", "Q2", "POLSINELLI PC", 314911, "TEVA PHARMACEUTICALS USA, INC.", 2019, "second_quarter", "PHA", "H.R.938, Bringing Low Cost Options & Competition While Keeping Incentives for New Generics (BLOCKING) Act\nH.R.965/ S.340, CREATES Act\nH.R.1503, Orange Book Transparency Act\nH.R.1520, Purple Book Continuity Act\nH.R.2374/ S.1224, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (STALLING) Act\nH.R.2375/ S.64, Preserve Access to Affordable Generics and Biosimilars Act\nH.R.2376/ S.1227, Prescription Pricing for the People Act\nS.1416, Affordable Prescriptions for Patients Act\nS.1895, Lower Health Care Costs Act\nH.R. 1499, Protecting Consumer Access to Generic Drugs Act\nAdministration review of drug pricing policies", "HOUSE OF REPRESENTATIVES,SENATE", 75000, null, 0, 0, "2019-07-11T10:40:32.103000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2301336"], "units": {}, "query_ms": 82.32741802930832, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}